The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

Inclusion Criteria

Concurrent Medication:

Allowed:

* AZT, ddI, ddC, d4T, or 3TC.
* Oral trimethoprim/sulfamethoxazole.
* Aerosolized pentamidine.
* Dapsone.
* Fluconazole.
* Rifabutin.
* Clarithromycin.

Patients must have:

* HIV seropositivity.
* Mean CD4 count \>= 100 cells/mm3.
* External anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. NOTE:
* Warts on anal, urethral, or vaginal mucosa will not be studied.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated.
* Active medical problems sufficient to hinder study compliance.

Concurrent Medication:

Excluded:

* Podofilox or any podophyllum resin preparation.
* Liquid nitrogen treatment.
* Interferon alpha.
* Trichloracetic acid.
* Other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity.
* Other investigative drugs (except d4T or 3TC) unless approved by the sponsor.

Patients with the following prior conditions are excluded:

History of untreated syphilis or Bowenoid papulosis.

Prior Medication:

Excluded within 4 weeks prior to study entry:

* Treatment for anogenital warts.
* Immunomodulators (including interferons or systemic corticosteroids).
* Lymphocyte replacement therapy.
* Biologic response modifiers. Substance abuse.